补充甲羟戊酸提高高龄女性整倍体胚胎形成率:随机对照试验方案
本研究为单中心前瞻性随机对照试验,拟纳入128例38-42岁接受PGT-A的不孕女性,随机分为甲羟戊酸(MVA)补充组与对照组,预计分析150个周期。主要结局为整倍体囊胚率,次要结局为冻融胚胎移植后的临床妊娠率与活产率。
要点
- MVA补充用于改善高龄女性卵母细胞 competence,尚处试验验证阶段。
- 主要结局为整倍体囊胚率,次要结局为FET后临床妊娠率与活产率。
- 研究为单中心RCT方案,结果尚未报告。
核心结论
- 该试验旨在评估MVA补充对高龄接受PGT-A女性整倍体囊胚率及临床妊娠结局的影响,结果尚未公布。
研究设计与样本
- 单中心、前瞻性、随机对照试验;计划纳入128例38-42岁接受PGT-A的不孕女性,预计分析150个周期。
关键数值与推荐
- 主要结局为整倍体囊胚率;次要结局为冻融胚胎移植后临床妊娠率与活产率。
- 研究对象为38-42岁接受PGT-A的不孕女性,随机分为MVA补充组与对照组。
临床怎么用
- 目前仅为研究方案,尚不能据此改变临床实践;需等待试验结果明确MVA补充的疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oocyte aneuploidy is a major cause of pregnancy failure in women of advanced maternal age (AMA), and current assisted reproductive technologies offer limited effective strategies to prevent age-related decline in oocyte quality. The mevalonate (MVA) pathway in granulosa cells has recently been implicated in supporting meiotic maturation, but its therapeutic potential in humans remains unclear. This randomized controlled trial is designed to evaluate the effects of MVA supplementation on oocyte competence in women of AMA undergoing preimplantation genetic testing for aneuploidy (PGT-A). METHODS: The study will be conducted as a single-center, prospective, randomized controlled trial. A total of 128 infertile women aged 38-42 years undergoing PGT-A will be enrolled and randomized to either the MVA supplementation group or the control group. Cumulus-oocyte complexes retrieved from each cycle will be allocated according to the randomization protocol, with an estimated 150 cycles analyzed. The primary outcome is the euploidy blastocyst rate, while the secondary outcomes are the clinical pregnancy rate and live birth rate following frozen embryo transfer (FET). DISCUSSION: This trial is expected to evaluate the effects of MVA supplementation on euploidy blastocyst rate and clinical pregnancy outcomes in women of AMA undergoing PGT-A. These findings may provide valuable insights into the potential application of MVA supplementation as an adjunct treatment for infertility in this population. TRIAL REGISTRATION: ClinicalTrials.gov NCT05788822. Registered in March 2023.
引用
- Wang S, Zhang Y, Wang L, et al. Mevalonate supplementation to enhance euploid embryo formation in women of advanced maternal age: a study protocol for a randomized controlled trial. Trials. 2026. PMID: 41689053. doi:10.1186/s13063-026-09522-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。